Read by QxMD icon Read

Total PSA Free PSA

Zipei Cao, Lijuan Wei, Weizhi Zhu, Xuping Yao
BACKGROUND: Reduction of cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16 and p14) expression through DNA methylation has been reported in prostate cancer (PCa). This meta-analysis was conducted to assess the difference of p16 and p14 methylation between PCa and different histological types of nonmalignant controls and the correlation of p16 or p14 methylation with clinicopathological features of PCa. METHODS: According to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria, articles were searched in PubMed, Embase, EBSCO, Wanfang, and CNKI databases...
March 2018: Medicine (Baltimore)
Ahmed S Zakaria, Alice Dragomir, Wassim Kassouf, Simon Tanguay, Armen Aprikian
OBJECTIVES: To characterize testosterone profile changes over time in a cohort of prostate cancer (PCa) patients managed with active surveillance (AS) and to assess its correlation with the initial disease characteristics and further progression. METHODS: We conducted retrospective chart review of PCa patients managed with AS. Patients were followed with PSA, total, free and bioavailable testosterone measurements, physical examination, and by repeat biopsies or periodic magnetic resonance imaging...
March 20, 2018: World Journal of Urology
A Gevorgyan, J-F Hétet, M Robert, V Duchattelle-Dussaule, L Corno, I Boulay, H Baumert
OBJECTIVE: To study the oncologic and functional results of salvage cryotherapy after failure of external radiotherapy and brachytherapy. MATERIALS AND METHODS: Patients treated by total salvage cryotherapy (3rd generation) in 2 centers (Groupe Hospitalier Saint-Joseph in Paris and Clinique Jule-Verne Nantes) in between January 2008 and April 2016 were included. The biochemical recurrence-free survival (BRFS) was calculated using the Phoenix criteria (PSA>nadir+2ng/mL)...
March 15, 2018: Progrès en Urologie
Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y Song, Theodore L DeWeese, Phuoc T Tran
BACKGROUND: Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. METHODS: A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR)...
March 9, 2018: Prostate
Brunno C F Sanches, Ana Luiza Lalli, Wilmar Azal Neto, Athanase Billis, Leonardo Oliveira Reis
PURPOSE: To explore the role of prostate biopsy core length on prediction of index tumor clinical significance and localization on radical prostatectomy (RP) and time to recurrence, hypothesizing 10-, 10-12-, or > 12-mm minimum core as potential biopsy quality control. METHODS: Assessed 2424 prostate biopsy cores and corresponding RP of 202 patients submitted to the first set of 12 cores prostate biopsy between 2010 and 2015. Analyzed biopsy core length, age, prostate volume (PV), free and total PSA ratio, PSA density, RP index tumor clinical significance, extension, localization, surgical margins, and cancer control...
March 1, 2018: World Journal of Urology
Hongzoo Park, Sang Wook Lee, Geehyun Song, Tae Wook Kang, Jae Hung Jung, Hyun Chul Chung, Sung Jin Kim, Chang Hoo Park, Jong Yeon Park, Tae Young Shin, In Bum Suh, Jeong Hyun Kim
BACKGROUND: We evaluated the clinical performance of [-2]proPSA (p2PSA) and its derivatives in predicting the presence and aggressiveness of prostate cancer (PCa) in Korean men. METHODS: A total of 246 men with total prostate-specific antigen (tPSA) ≥ 3.5 ng/mL who underwent their first prostate biopsy were included in this prospective, multicenter, observational study. Diagnostic accuracy of tPSA, free-to-total PSA ratio (%fPSA), p2PSA, %p2PSA, and the Beckman Coulter prostate health index (PHI) was assessed by receiver operating characteristic curve analyses and logistic regression analyses...
March 12, 2018: Journal of Korean Medical Science
Michael A Maccini, Nicholas J Westfall, Adrie Van Bokhoven, Marshall Scott Lucia, Wendy Poage, Paul D Maroni, Shandra S Wilson, Leonard Michael Glodé, Paul Arangua, Jay Newmark, Mitchell Steiner, Priya N Werahera, Elward David Crawford
BACKGROUND: The 4Kscore is a new commercially available blood-based diagnostic test which predicts risk for aggressive, clinically significant prostate cancer on prostate biopsy. The 4Kscore is currently restricted to patients who have not had a digital rectal exam (DRE) in the previous 96 h, owing to prior mixed data suggesting that prostate specific antigen (PSA) isoforms may increase by a statistically significant-if not necessarily clinically significant-amount shortly after DRE...
February 19, 2018: Prostate
Zhenzhen Jia, Yuehong Shu, Renlong Huang, Junguang Liu, Lingling Liu
Novel supermacroporous PSA-nZVI composites with nanoscale zero-valent iron particles (nZVI) embedded into poly (sodium acrylate) (PSA) cryogels were synthesized through ion exchange followed by in-situ reduction. The magnetic composites were evaluated for material characterizations and their efficiency for Cr(VI) and total Cr removal from aqueous medium in batch experiments. PSA-nZVI composites with high nZVI loading capacity up to 128.70 mg Fe/g PSA were obtained, and the interconnected macroporous structure of PSA cryogel remained unaltered with nZVI uniformly distributed on PSA cryogel as determined by TGA, SEM, TEM, XRD and XPS analyses...
February 7, 2018: Chemosphere
Mohammed Ibrahim, Siddhartha Yadav, Foluso Ogunleye, Dana Zakalik
BACKGROUND: Mutations in BRCA1 and BRCA2 (BRCA1/2) genes are associated with an increased risk of breast and ovarian cancers in women. The cancer characteristics of men with BRCA1/2 mutations are less well studied. This study describes the unique cancer characteristics of male BRCA1/2 mutation carriers at our institution. METHODS: We performed a retrospective chart review on male patients who were seen between January 2004 and December 2014 and tested positive for a BRCA1/2 mutation...
February 13, 2018: BMC Cancer
Nigel P Murray, Socrates Aedo, Cynthia Fuentealba, Eduardo Reyes, Anibal Salazar
Introduction: Minimal residual disease (MRD) remaining after curative therapy for prostate cancer has the potential for growth and can result in metastasis. Circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) could represent different types of MRD. We here determined; biochemical failure free survival rates; time to BF after 10 years follow-up; and the presence of CPCs and mM in patients treated with radical prostatectomy (RP) for prostate cancer. Methods and Patients: One month after RP, blood and bone marrow were sampled for assessment of CPCs and mM...
January 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
Andrew Vickers, Emily A Vertosick, Daniel D Sjoberg, Freddie Hamdy, David Neal, Anders Bjartell, Jonas Hugosson, Jenny L Donovan, Arnauld Villers, Stephen Zappala, Hans Lilja
PURPOSE: The four kallikrein panel, commercially available as the 4kScore, is a statistical model that has been shown to predict accurately both Gleason grade group ≥2 (high-grade) cancer on biopsy and long-term risk of distant prostate cancer metastases. The panel includes two novel markers, intact prostate specific antigen (PSA) and human kallikrein-related peptidase 2 (hK2). It has been questionned whether these two additional markers add discrimination to the clinical predictors (age, digital rectal exam, prior biopsy) and established molecular markers (total and free PSA)...
January 20, 2018: Journal of Urology
Hitoshi Ishii, Matthew Madin-Warburton, Alena Strizek, Lucy Thornton-Jones, Shuichi Suzuki
AIMS: Dulaglutide is a new once weekly glucagon-like peptide-1 (GLP-1) receptor agonist administered via a disposable auto-injection pen for the management of type 2 diabetes mellitus (T2DM). The objective of this study was to estimate the cost-effectiveness of dulaglutide vs insulin glargine for the management of T2DM from a Japanese healthcare perspective, in accordance with recently approved Japanese Cost-Effectiveness Guidelines. METHODS: The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine...
February 7, 2018: Journal of Medical Economics
Angeles Sanchis-Bonet, Marta Barrionuevo-González, Ana Bajo-Chueca, Nelson Morales-Palacios, Manuel Sanchez-Chapado
INTRODUCTION: To assess whether [-2]pro-prostate-specific antigen (p2PSA) meets the criteria to justify its inclusion in a predictive model of prostate cancer (PCa) diagnosis and in the clinical decision-making process. MATERIALS AND METHODS: A total 172 men with total prostate-specific antigen of 2-10 ng/mL underwent measurement of free PSA and p2PSA before prostate biopsy in an observational and prospective study. From these measurements, the Prostate Health Index (PHI) was calculated...
January 18, 2018: Urologia Internationalis
C Huang, G J Ji, G Song, H Wang, Y K Chen, L Q Zhou
Objective: To develop a predictive nomogram based on multi-parametric magnetic resonance imaging (mpMRI) information to identify men more likely to have a cancer diagnosed on repeat prostate biopsy. Methods: The clinical data of 237 patients who received repeat prostate biopsy after initial negative biopsy from Department of Urology of Peking University First Hospital between January 2001 and August 2016 was reviewed. Patient age, body mass index (BMI), serum total prostate-specific antigen (PSA), percent free PSA (f/t), prostate volume (PV), PSA density (PSAD), PSA velocity (PSAV), digital rectal examination (DRE), transrectal ultrasound (TRUS)and mpMRI results were included in the univariate and multivariate analysis...
January 9, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Aileen Duffton, Azmat Sadozye, Lynsey Devlin, Nicholas MacLeod, Carolynn Lamb, Suzanne Currie, Philip McLoone, Marimuthu Sankaralingam, John Foster, Stephanie Paterson, Stefanie Keatings, David Dodds
OBJECTIVE: To investigate feasibility and safety of stereotactic ablative radiotherapy in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial marker seeds for positioning and Varian RapidArc with flattening filter free (FFF) delivery. METHODS: 41 patients were treated for low-intermediate risk prostate cancer with initial prostate-specific antigen of ≤20 ng ml-1, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate ±seminal vesicles...
February 1, 2018: British Journal of Radiology
S Lazarev, M R Thompson, N N Stone, R G Stock
OBJECTIVES: To examine biochemical control, survival, and late morbidity with definitive low-dose-rate brachytherapy (LDR-BT) for prostate cancer patients surviving ≥10 years post-treatment. MATERIALS AND METHODS: We identified 757 men with localized prostate cancer who underwent definitive LDR-BT in the period 1990-2006 and were followed for ≥10 years at our institution. Biochemical failure-free survival (BFFS), distant metastases-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were selected as study endpoints...
January 10, 2018: BJU International
Liancheng Fan, Rui Wang, Chenfei Chi, Wen Cai, Yong Zhang, Hongyang Qian, Xiaoguang Shao, Yanqing Wang, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Lixin Zhou, Baijun Dong, Wei Xue
OBJECTIVE: To compare the antitumor effect of abiraterone (AA) followed by docetaxel-prednisone (DP) or vice versa in metastatic castration-resistant prostate cancer (mCRPC) patients, and explored factors that might predict combined PSA-PFS, combined rPFS and OS. PATIENTS AND METHODS: We retrospectively analyzed mCRPC patients treated with sequential therapy using DP followed by AA or vice versa. Patients who had received enzalutamide or cabazitaxel were excluded...
March 2018: Prostate
Ilker Tinay, Güven Aslan, Ali Riza Kural, Haluk Özen, Bülent Akdoğan, Asıf Yıldırım, Şakir Ongün, Alp Özkan, Tarik Esen, Ferruh Zorlu, Özdal Dillioğlugil, Nural Bekiroglu, Levent Türkeri
INTRODUCTION: To evaluate the pathological outcomes of Turkish men meeting the criteria for Active Surveillance (AS), who elected to undergo immediate radical prostatectomy (RP). MATERIAL AND METHODS: Retrospective analysis including 1,212 patients with clinically localized prostate cancer (PCa) who met the eligibility criteria for AS. The primary outcomes were pathological upstaging and pathological upgrading. RESULTS: Nine hundred ninety-one patients were eligible for analysis after the central review of the submitted data...
December 22, 2017: Urologia Internationalis
Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, Costantine Albany, Mark N Stein, Lakshmi P Kunju, Javed Siddiqui, Yi-Mi Wu, Dan Robinson, Robert J Lonigro, Xuhong Cao, Scott A Tomlins, Rohit Mehra, Kathleen A Cooney, Bruce Montgomery, Emmanuel S Antonarakis, Daniel H Shevrin, Paul G Corn, Young E Whang, David C Smith, Megan V Caram, Karen E Knudsen, Walter M Stadler, Felix Y Feng, Arul M Chinnaiyan
Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients and Methods Patients underwent metastatic site biopsy and were stratified by ETS status and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ETS fusions predicted response...
December 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Tobias Nordström, Olof Akre, Markus Aly, Henrik Grönberg, Martin Eklund
BACKGROUND: Screening for prostate cancer using prostate-specific antigen (PSA) alone leads to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early evidence on its use for biopsy decisions was conflicting and use of PSA density is not commonly recommended in guidelines. METHODS: We analyzed biopsy outcomes in 5291 men in the population-based STHLM3 study with PSA ≥ 3 ng/ml and ultrasound-guided prostate volume measurements by using percentages and regression models...
December 19, 2017: Prostate Cancer and Prostatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"